These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8962321)

  • 1. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone metal mobilization induced by long-term desferrioxamine B therapy in continuous ambulatory peritoneal dialysis.
    Romero RA; Salgado O; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3380-1. PubMed ID: 8962319
    [No Abstract]   [Full Text] [Related]  

  • 3. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
    Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA; McParland C; Keogh JA
    Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of plasma aluminum in the detection and prevention of aluminum toxicity.
    Winney RJ; Cowie JF; Robson JS
    Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005
    [No Abstract]   [Full Text] [Related]  

  • 13. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
    McCarthy JT; Kurtz SB; Mussman GV
    Am J Med; 1987 Feb; 82(2):367-70. PubMed ID: 3812538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 16. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of long-term hemodialysis on changes in the concentration of various trace elements in the blood of patients with chronic renal failure].
    Weyde W; Adamiec R
    Pol Tyg Lek; 1983 Jan; 38(2):45-9. PubMed ID: 6856497
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of dialysis osteomalacia with desferrioxamine.
    Brown DJ; Dawborn JK; Ham KN; Xipell JM
    Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.